Ventas, Inc. (VTR) Stock Price & Analysis
Ventas, Inc. (VTR) closed at USD 86.99 on Thursday, October 22, 2026, up 1.89% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 86.99; the Oct 22, 2026 session ranged USD 85.51–87.22 on volume of 2,752,267 shares. Market capitalization is —, with a 52-week range of USD 68.15–101.6 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 11:04 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VTR.md
Key facts (VTR)
- Last four reported quarters (through Jun 30, 2026): revenue $6.44B, net income $273M (4.2% margin) (SEC filings).
- 1 of 80 tracked superinvestors hold VTR (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y +27.4% vs S&P 500 +14.9%; 5Y +86.4% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 0.11, revenue estimate $1.78B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VTR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.83B | $4.13B | $4.50B | $4.92B | $5.83B | $6.44B |
| Net income | $56.6M | -$40.9M | -$30.3M | $88.4M | $262M | $273M |
| EPS (diluted) | $0.13 | -$0.12 | -$0.10 | $0.19 | $0.54 | — |
| Free cash flow | -$776M | $219M | $470M | -$1.20B | -$1.28B | — |
| Net margin | 1.5% | -1.0% | -0.7% | 1.8% | 4.5% | 4.2% |
| Revenue growth | +0.9% | +7.9% | +8.9% | +9.5% | +18.5% | — |
| Cash + short-term investments | $150M | $123M | $509M | $898M | $741M | — |
| Total debt | $12.3B | $12.7B | $13.5B | $13.5B | $13.0B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (VTR)
P/E at fiscal year-ends: Dec 2025 136.9x, Dec 2024 277.5x.
Superinvestors (SEC 13F-HR, Q2 2026) (VTR)
1 of 80 tracked investors hold VTR. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Christopher Davis | Davis Advisors | 0.04% | $9.9M | Reduced -2.1% |
Analysts (VTR)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Wells Fargo | Target lowered | Overweight | $104 → $96 |
| 2026-10-13 | Barclays | Target lowered | Equal-Weight | $102 → $91 |
| 2026-09-21 | Evercore ISI Group | Target lowered | Outperform | $101 → $100 |
| 2026-09-02 | Scotiabank | Target raised | Sector Perform | $93 → $95 |
| 2026-09-01 | Wells Fargo | Target raised | Overweight | $96 → $104 |
| 2026-08-31 | Barclays | Target raised | Equal-Weight | $99 → $102 |
| 2026-08-14 | RBC Capital | Target raised | Outperform | $98 → $99 |
| 2026-08-11 | BMO Capital | Target raised | Outperform | $105 → $107 |
| 2026-08-04 | Citigroup | Target raised | Buy | $100 → $110 |
| 2026-07-31 | Cantor Fitzgerald | Target raised | Overweight | $97 → $102 |
| 2026-07-22 | Mizuho | Target raised | Outperform | $98 → $104 |
| 2026-07-07 | Barclays | Initiated | Overweight → Equal-Weight | $99 |
Total return (dividends reinvested) (VTR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +27.4% | +86.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +27.5% | +13.2% |
| Volatility (annualized) | 22.8% | 24.8% |
| Max drawdown | -19.9% (Jul 2026→Oct 2026) | -41.5% (Mar 2022→Oct 2022) |
VTR revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| SHOP | $1.36B | 78.8% | +32.0% |
| OM&R | $229.3M | 13.3% | +3.5% |
| NNN | $124.9M | 7.2% | -18.2% |
| Total revenue | $1.73B | 100% | — |
VTR revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Third-party capital management expenses | $4.2M | 0.2% | -3.5% |
| Management Service | $3.8M | 0.2% | -2.6% |
| Total revenue | $1.73B | 100% | — |
VTR revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $5.21B | 89.3% | +19.3% |
| Canada | $552.9M | 9.5% | +5.0% |
| United Kingdom | $71.2M | 1.2% | +131.7% |
| Total revenue | $5.83B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
VTR suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Nationwide Health Properties | “We own a majority interest in NHP/PMB L.P. ("NHP/PMB"), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC ("PMB").” |
| Partner | Pacific Medical Buildings | “We own a majority interest in NHP/PMB L.P. ("NHP/PMB"), a limited partnership formed in 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC ("PMB").” |
| Partner | Ventas Realty | “•In August 2025, we increased the amount that Ventas Realty, Limited Partnership ("Ventas Realty") may issue from time to time under its commercial paper program from a maximum aggregate amount outstanding at any time of $1.0 billion to $2.0 billion.” |
Quoted from the company's 10-K filed Feb 6, 2026.
Companies that name VTR in their SEC reports
| Relationship to VTR | Company | Filing | Sentence |
|---|---|---|---|
| related | Ardent Health, Inc. (ARDT) | 10-K Mar 16, 2026 | “For additional information regarding the terms of the Ventas Master Lease, see Note 4, Related Party Transactions, to our consolidated financial statements included within this Annual Report.” |
VTR customer concentration
In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (2.3%, 2%) of revenue, per the company's 10-Q filed Jul 30, 2026. The company does not name them.
VTR company outlook (results filed Jul 29, 2026)
- “The Company's 2026 guidance contains forward-looking statements and is based on a number of assumptions, including those identified later in this press release; actual results may differ materially.”
Quoted word-for-word from the SEC 8-K results press release.
VTR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.11 | $0.15 | -26.7% | $1.78B | 3 |
| Next quarter (ends Dec 2026) | $0.13 | $0.17 | -21.6% | $1.81B | 3 |
| Current fiscal year (ends Dec 2026) | $0.44 | $0.54 | -17.8% | $6.99B | 1 |
| Next fiscal year (ends Dec 2027) | $0.79 | $0.85 | -6.7% | $7.85B | 2 |
VTR options: expected move
Options price a move of about ±6.0% (±$5.23) by Nov 20, 2026, which includes earnings on Oct 27, 2026. Over the last 8 reports the stock moved ±4.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 26.6% | ±6.0% |
| Dec 18, 2026 | 56 | 27.2% | ±8.6% |
| Jan 15, 2027 | 84 | 24.5% | ±9.5% |
| Feb 19, 2027 | 119 | 23.5% | ±10.7% |
| May 21, 2027 | 210 | 24.6% | ±14.8% |
30-day implied volatility 25.4% vs 20.8% realized over the last 30 trading days. Put/call ratio (volume) 0.97. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 11:04 UTC)
| Price | USD 86.99 |
|---|---|
| Change | ▲ 1.89% (up) |
| Previous Close | USD 86.99 |
| Open | USD 86.99 |
| Day Range | USD 85.51 – 87.22 |
| 52-Week Range | USD 68.15 – 101.6 |
| Volume | 2,752,267 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (VTR)
Nexqual's technical model rates VTR "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 11:04 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 54.6 (neutral) |
| vs SMA50 | Below (USD 87.97) |
| MACD | -0.52 (negative) |
Earnings (VTR)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 0.11 |
| Revenue Estimate | $1.78B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.17 vs est 0.11 ▲ beat |
| 2026-03-31 | USD 0.1 vs est 0.1 ▼ miss |
| 2025-12-31 | USD 0.13 vs est 0.09 ▲ beat |
| 2025-09-30 | USD 0.12 vs est 0.05 ▲ beat |
Source: Nexqual, October 23, 2026 at 11:04 UTC.
Financials & Fundamentals (VTR)
| Total Revenue | $6.42B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +21.70% |
| Gross Margin | +39.97% |
| Operating Margin | +14.81% |
| Profit Margin | +4.09% |
| ROE | +2.01% |
| Debt / Equity | 0.85 |
| Current Ratio | 0.3 |
| Total Cash | $198.96M |
| Total Debt | $12.92B |
Source: Nexqual, October 23, 2026 at 11:04 UTC.
Ownership (VTR)
| Insider Ownership | +0.51% |
|---|---|
| Institutional Ownership | +105.57% |
| Shares Outstanding | 512.95M |
| Float | 510.51M |
| Short % of Float | +3.69% |
Source: Nexqual, October 23, 2026 at 11:04 UTC.
From Ventas, Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- In order to support our SHOP segment, we developed Ventas OI™, a proprietary data and analytics platform, to provide us with timely access to high-quality data that informs real-time decisions.
- Sources of revenue for our senior housing communities in the United Kingdom include federal (including the National Health Service) and local governmental authorities in addition to private payors.
- Through Ventas OI™, we collect and assess data from a variety of sources, including proprietary data from our senior housing operations and external data sources.
- Our objective is to generate reliable and growing cash flows from our portfolio, which enables us to pay regular cash dividends to stockholders and creates opportunities to increase stockholder value.
Partnerships
- Through VIM, we partner with third-party institutional investors to invest in real estate through various joint ventures and other co-investment vehicles where we are the sponsor or general partner, including our open-ended investment vehicle, the Ventas Life Science & Healthcare Real Estate Fund (the "Ventas Fund").
Legal & Regulatory Risks (Item 1A, quoted)
- We and our managers, tenants and borrowers may be adversely affected by regulation and enforcement.
- The laws and regulations that apply to us and our managers, tenants and borrowers are complex and may change rapidly or new laws and regulations may be introduced, and efforts to comply with them require significant resources.
- Our investments may expose us to unknown liabilities.
- We may acquire or invest in properties or businesses that are subject to liabilities and without any recourse, or with only limited recourse, against the prior owners or other third parties with respect to unknown liabilities.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OHI | Omega Healthcare Investors, Inc | USD 46.3 | ▲ 4.16% |
| DOC | Healthpeak Properties, Inc. | USD 19.34 | ▲ 4.65% |
| AHR | American Healthcare REIT, Inc. | USD 53.4 | ▲ 1.02% |
| WELL | Welltower Inc. | USD 237.4 | ▲ 1.37% |
| CTRE | CareTrust REIT, Inc. | USD 36.62 | ▲ 2.72% |
| HR | Healthcare Realty Trust Incorpo | USD 17.93 | ▲ 4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:04 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt